Evidence Summary

Itraconazole is one of the better-known drug-repurposing candidates in oncology because it combines broad pathway relevance with an established non-cancer medical history.

Research Overview

1. Multiple pathway-based studies support Hedgehog, angiogenesis, AKT / mTOR, Wnt / β-catenin, and multidrug-resistance effects

2. Early clinical data exists in metastatic prostate cancer, NSCLC, and basal cell carcinoma

3. Retrospective combination studies suggest meaningful signal in ovarian, breast, and pancreatic cancer settings

4. Clinical oncology data is promising but still limited by size, design, and heterogeneity

5. Most evidence supports adjunctive or combination use rather than standalone use

Clinical Application Status

Approved status: Approved as an antifungal medicine, not as an approved cancer drug.

Clinical use: Used experimentally in repurposed-drug and investigational oncology strategies.

Evidence strength: Moderate, with meaningful early human signals but limited large randomised oncology trials.

Key Advantages

1. Multi-pathway action — inhibits several oncogenic survival pathways at once

2. Anti-angiogenic relevance — especially through VEGFR2-related effects

3. Repurposed-drug practicality — already globally available as a known medicine

4. Combination potential — often explored alongside standard chemotherapy

5. Favourable baseline safety familiarity — relative to novel experimental agents

Key Considerations

1. Clinical evidence remains early — most studies are small or retrospective

2. Combination logic matters — itraconazole is mostly being explored as an adjunct

3. Drug interaction review is essential — itraconazole has meaningful CYP interaction relevance

4. Long-term resistance questions remain open

5. Dosing in cancer settings differs from standard antifungal use

Bottom line

Itraconazole is a credible repurposed-drug candidate with real early oncology relevance. It should be understood as an investigational adjunct with multi-pathway promise, not as a proven replacement for standard treatment.

Key References

Repurposing itraconazole for the treatment of cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/

Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy
https://www.sciencedirect.com/science/article/abs/pii/S1043661821003328

Itraconazole as a Candidate for Drug Repurposing in Oncology
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/